Details of the Drug

General Information of Drug (ID: DMHTY9W)

Drug Name
Ublituximab
Synonyms TG-1101
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [2]
Lymphoma 2A80-2A86 Phase 1/2 [3]
Nodal marginal zone lymphoma 2A85.0 Phase 1/2 [3]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB11850
TTD ID
D0A8GM
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761238.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.